Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Cash from Financing Activities: 2018-2024

Historic Cash from Financing Activities for Stoke Therapeutics (STOK) over the last 7 years, with Dec 2024 value amounting to $131.1 million.

  • Stoke Therapeutics' Cash from Financing Activities fell 61.76% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 95.93%. This contributed to the annual value of $131.1 million for FY2024, which is 147.31% up from last year.
  • Latest data reveals that Stoke Therapeutics reported Cash from Financing Activities of $131.1 million as of FY2024, which was up 147.31% from $53.0 million recorded in FY2023.
  • Stoke Therapeutics' Cash from Financing Activities' 5-year high stood at $131.1 million during FY2024, with a 5-year trough of $1.3 million in FY2021.
  • For the 3-year period, Stoke Therapeutics' Cash from Financing Activities averaged around $76.8 million, with its median value being $53.0 million (2023).
  • As far as peak fluctuations go, Stoke Therapeutics' Cash from Financing Activities crashed by 98.81% in 2021, and later soared by 3,514.41% in 2022.
  • Stoke Therapeutics' Cash from Financing Activities (Yearly) stood at $108.1 million in 2020, then tumbled by 98.81% to $1.3 million in 2021, then skyrocketed by 3,514.41% to $46.4 million in 2022, then climbed by 14.22% to $53.0 million in 2023, then spiked by 147.31% to $131.1 million in 2024.